Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates

View original at seekingalpha.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates Earnings Call Insights: Avery Dennison Corporation (AVY) Q4 2025 MANAGEMENT VIEW * Deon Stander, President, CEO & Director, stated the company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025,…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • High-value categories have margins a number of points above the company's average, and significantly above base categories

    80% confidence
  • High-value categories in Solutions Group make up 60% of the portfolio

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation, strengthen service and quality, shorten innovation cycles and provide more data-driven solutions

    80% confidence
  • The company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025

    80% confidence
  • High-value categories are a number of points above average margin, significantly above the base categories as well

    80% confidence
  • Restructuring benefits expected to be somewhat balanced across the year

    80% confidence
  • High-value categories margins are a number of points above company average, and significantly above base categories

    80% confidence
  • High-value categories helped balance base categories, which were down low single digits in the quarter on softer customer volumes

    80% confidence
  • Higher working capital was due to high-value category mix, and CapEx will support both productivity and future capacity

    80% confidence
  • Vestcom grew over 10% in Q4

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation, strengthen service and quality, shorten innovation cycles and provide more data-driven solutions

    80% confidence
  • The temporary savings headwind is on an order of magnitude basis probably pretty similar to the size of the restructuring actions, that $50 million

    80% confidence
  • Solutions Group high-value categories make up 60% of portfolio with Vestcom growing over 10%

    80% confidence
  • Company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025, demonstrating the durability of the franchise and ability to activate multiple levers across a range of macro scenarios

    80% confidence
  • High-value categories are a number of points above our average margin, certainly significantly above the base categories as well

    80% confidence
  • Intelligent Labels growth rate in 2026 anticipated to be above what was delivered in 2025

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • Compliance enforcement in general retail is expected to provide a tailwind, and the company is expanding logistics pilots with new customers

    80% confidence
  • Base volumes were a bit soft in the quarter

    80% confidence
  • Growth acceleration will be driven by new customer acquisition, faster innovation cycles, and leveraging digital and AI investments

    80% confidence
  • In the fourth quarter, we delivered solid adjusted earnings per share of $2.45, up 3% compared to prior year

    80% confidence
  • Continue to drive ongoing productivity all the time in terms of ELS savings, looking at reducing scrap, being more efficient in our operations

    80% confidence
  • Walmart announcement increased pipeline interest for Intelligent Labels

    80% confidence
  • Given key economic indicators remain largely consistent with 2025 levels, we are not planning for any macroeconomic tailwinds in the near term

    80% confidence
  • Key economic indicators remain largely consistent with 2025 levels, no macroeconomic tailwinds planned in the near term

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • Company feels confident in paper supply risk management

    80% confidence
  • Temporary savings headwind is on an order of magnitude basis probably pretty similar to the size of the restructuring actions, approximately $50 million

    80% confidence
  • The company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025, demonstrating the durability of the franchise and ability to activate multiple levers across a range of macro scenarios

    80% confidence
  • The temporary savings headwind is on an order of magnitude probably similar to the size of the restructuring actions, approximately $50 million

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates — Source | Via News | ViaNews EU